MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET
Company Participants
Zack Armen - Head of Investor Relations at MiNK
Jennifer Buell - President and Chief Executive Officer
Christine Klaskin - Principal Financial and Accounting Officer
Conference Call Participants
Emily Bodnar - H.C. Wainwright
Kalpit Patel - B. Riley
Jack Allen - Baird
Matt Phipps - William Blair
Operator
Good morning, and welcome to MiNK Therapeutics' Fourth Quarter and Full Year 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note, this event is being recorded. If anyone has any objections, you may disconnect at this time.
I will now turn the call over to Zack Armen, Head of Investor Relations at MiNK.
Zack Armen
Thank you, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will contain forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans as well as time lines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.
Joining me today on the call are Dr. Jennifer Buell, President and Chief Executive Officer; and Christine Klaskin, Principal Financial and Accounting Officer.
Now I'd like to turn the call over to Dr. Buell to highlight our progress in 2022 and plans for the year ahead.
Jennifer Buell
Thank you so much, Zack. Good morning, everyone. Thanks for joining our fourth quarter and full year 2022 earnings call. It's a great pleasure to be with you today and to share an update on the progress of our company. And I'm really excited and proud to share that our dedication to advance the field of cell therapy has yielded a quite exciting and differentiated results in 2022 and set us up for a very active 2023.
We've made important strides in advancing iNKT cells, our platform and generating critical data in research as well as in the clinic, some of which we've already presented publicly and more of which will be coming your way this year. Recall that agenT-797, our lead product advancing in the clinic is an allogeneic, unmodified or naked iNKT cell.
These cells have shown promise as a monotherapy as well as in combination with approved anti-PD-1 KEYTRUDA or OPDIVO in clinical trials, and these are trials in patients that are heavily pretreated with solid tumor cancers. We're excited to present an update on this progress at the upcoming AACR meetings next month. And we'll also be announcing our plans for developing iNKT solid tumor cancers, such as non-small cell lung cancer and relapsed refractory gastric cancer in collaboration with world leaders in these diseases.